Double Mutant COVID Variant Shows Enhanced Host Cell Entry

B.1.617, the double mutant variant of coronavirus that has emerged in India, entered certain types of lung and intestine cells with slightly increased efficiency.

B.1.617, the double mutant variant of coronavirus that has emerged in India, entered certain types of lung and intestine cells with slightly increased efficiency compared with the original wild-type strain, said researchers.

The researchers, including Markus Hoffmann from German Primate Center, also reported that the entry of B.1.617 into the lung and intestinal cells was blocked following treatment with soluble angiotensin-converting enzyme 2 (ACE2) or the serine protease inhibitor Camostat.

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

‘The sharp rise in COVID-19 cases and deaths in India over recent weeks is thought to be caused by the novel variant B.1.617, which harbors eight mutations in the spike protein. ’

However, this host cell entry was not blocked by the monoclonal antibody Bamlanivimab, which has received emergency use authorisation (EUA) as a Covid-19 treatment.

Finally, B.1.617 also partially evaded neutralisation by the antibodies induced through natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine, a study that appeared in the pre-print repository medRxiv, suggested.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

The researcher said that antibody evasion by B.1.617 may contribute to the rapid spread of this variant.

These include the RBD mutations L452R and E484Q, which are known to modulate antibody-mediated neutralisation.

COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.

However, the researchers said it is not currently known whether B.1.617 resists this antibody-mediated neutralization.

To test whether B.1.617 is more adept at entering cells, the researchers infected eight cell lines with pseudotyped virus particles expressing spike protein from the original wild-type virus, the B.1.617 variant, or the B.1.351 variant.

Mucormycosis (Black Fungal Disease): A Complication of COVID-19
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.

Of the eight cell lines tested, the spikes of B.1.617 and B.1351 mediated entry into Calu-3 lung cells and Caco-2 colon cells with slightly increased efficiency, compared with the original strain.

Collectively, the study reveals that antibody evasion by B.1.617 may contribute to the rapid spread of this variant, the team noted.

Source-IANS